CG
LPCN icon

Cutler Group’s Lipocine LPCN Stock Holding History

Cutler Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-241
Closed -$1K – 4574
2018
Q1 		$1K Buy
+241
New +$6.71K ﹤0.01% 4087
2017
Q1 		– Sell
-153
Closed -$3K – 6836
2016
Q4 		$3K Buy
+153
New +$9.69K ﹤0.01% 5336
2016
Q2 		– Sell
-1,318
Closed -$23K – 6990
2016
Q1 		$23K Buy
1,318
+1,071
+434% +$183K ﹤0.01% 3133
2015
Q4 		$11K Buy
+247
New +$51.8K ﹤0.01% 4038

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's LPCN Position: Q4 2023 in Review

Cutler Group sold out of Lipocine (LPCN) in Q4 2023, closing a stake of 765 shares — an estimated $2K sold.

Cutler Group first reported a position in LPCN in Q4 2015 and held it in 32 quarters. The position peaked at $182K in Q1 2016. 19 funds tracked by Wall St. Rank hold LPCN as of Q4 2023.

  • Cutler Group reported no remaining Lipocine position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 765 Lipocine shares in Q4 2023, an estimated $2K.
  • Cutler Group first reported a position in Lipocine in Q4 2015 and held it in 32 quarters.
  • Cutler Group's Lipocine position peaked at $182K in Q1 2016.
  • 19 funds tracked by Wall St. Rank held Lipocine as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.